Doug Reed, PhD
Aerobiology Manager, RBL|
3501 Fifth Avenue
Pittsburgh, Pennsylvania 15261
Phone: (412) 648-1922
Bowling, Jennifer Dianne
Reed, Douglas S
Stinson, Elizabeth Marie
Dr. Reed did his doctoral work at the University of Texas Southwestern Medical Center at Dallas, working on thymocyte development in vitro. In 1995 Dr. Reed completed his dissertation and moved to Connecticut, where he worked as a postdoctoral fellow in the laboratory of Dr. Leo Lefrancois studying T lymphocyte activation in response to antigens entering through the small intestine. Dr. Reed became a principal investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in 1999, developing animal models to aerosolized pathogens and conducting efficacy studies in those models. While at USAMRIID Dr. Reed conducted and supervised aerosol exposures of animals including rodents, rabbits, and nonhuman primates. Dr. Reedís research at USAMRIID included developing nonhuman primate models of aerosol exposure to Venezuelan, Western, and Eastern Equine Encephalitis and evaluating candidate vaccines in those models, developing rodent and nonhuman primate models of aerosol exposure to Marburg and Ebola viruses, and evaluating a GMP-grade recombinant plague vaccine in mice against pneumonic plague. Dr. Reed is currently the Aerobiology Manager of the Regional Biocontainment Laboratory, working with collaborators to develop animal models of aerosol exposure to pathogens that are either biodefense threats or emerging infectious diseases.
My research is focused on three primary areas: 1) the immune response to tularemia; 2) the role of the immune response in viral encephalitis; and 3) respiratory infection of animals with infectious agents.
Francisella tularensis, a gram negative coccobacillus, is the causative agent of tularemia. In humans it has been shown that as few as 15 organisms can cause disease and pneumonic tularemia has a 30% mortality rate if untreated. There is concern that F. tularensis could be used as a biological weapon so vaccine and antibiotics that can treat tularemia are urgently needed. In my laboratory we have developed a rabbit model of pneumonic tularemia. In collaboration with Dr. Eileen Barry of the University of Maryland we have used this rabbit model to demonstrate that mutants of virulent F. tularensis that lack genes in key biosynthesis pathways are attenuated and efficacious against aerosol challenge with virulent F. tularensis. In addition to advancing those candidates towards clinical trials we are actively exploring the immune mechanisms that are important for protection.
In collaboration with Dr. Kate Ryman, Dr. William Klimstra and Dr. Amy Hartman we are working on animal models of viral encephalitis including Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, and Rift Valley Fever virus. The pathogenesis seen in these infections are remarkably similar in rodent and nonhuman primate models suggesting similar mechanisms that are responsible for determining the outcome. We are actively exploring development of new nonhuman primate models and evaluation of potential medical countermeasures (vaccines and therapeutics) for the treatment or prevention of these diseases.
The Regional Biocontainment Laboratory in the BST3 has an Aerobiology suite capable of exposing animals to aerosols containing pathogenic viruses, bacteria and toxins. Aerosols are performed inside a class III biological safety cabinet inside the suite and can accommodate both BSL-2 and BSL-3 pathogens. We use a state-of-the-art computer controlled aerosol management platform, the AeroMP that was developed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and that now is licensed and sold by Biaera Technologies (Hagerstown, MD). This system can accommodate a number of exposure chambers, aerosol generators and aerosol sampling devices. The flexibility of the AeroMP system allows for exposure of a wide variety of species including rodents, ferrets, rabbits, and nonhuman primates. We are one of only a few facilities in the world that has exposed marmosets to aerosolized pathogens.
- Reed, D.S.*, Glass, P.J.*, Bakken, R.R., Barth, J.F., Lind, C.M., Hart, M.K., Rayner, J., Alterson, K., Custer, M., Dudek, J., Owens, G., Kamrud, K.I., Parker, M.D., Smith, J. 2014. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitic viruses. J. Virol. 88(20):12077-86 *- equal contribution
- Reed, D.S., Smith, L., Cole, K.S., Santiago, A.E., Mann, B.J., Barry, E.M. 2014. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun 82(5):2098-2105 PMID: 24614653
- Caroline, A.L., Powell, D.S., Bethel, L.M., Oury, T.D., Reed, D.S., Hartman, A.L. 2014. Broad spectrum antiviral activity of Favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever in Wistar-Furth rats. PLoS Negl Trop Dis 8(4):e2790 PMID: 24722586
- Reed, D.S., Bethel, L.M., Powell, D.S., Hartman, A.L. 2014. Differences in aerosolization of Rift Valley Fever virus resulting from choice of inhalation exposure chamber: implications for animal challenge studies. Pathog Dis PMID: 24532259
- Hartman, A.L., Powell, D.S., Bethel, L.M., Caroline, A.L., Schmid, R.J., Oury, T., Reed, D.S. 2014. Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets. J. Virol. 88(4):2235-2245. PMID: 24335307
- Scanga, C.A., Lopresti, B.J., Tomko, J., Frye, L.J., Coleman, T.M., Fillmore, D., Carney, J.P., Lin, P.L., Flynn, J.L., Gardner, C.L., Sun, C., Klimstra, W.B., Ryman, K.D., Reed, D.S., Fisher, D.J., Cole, K.S. 2014. In vivo imaging in an ABSL-3 regional biocontainment laboratory. Pathog Dis. 71(2):207-212 PMID: 24838691
- Powell, D.S., Walker, R.C., Heflin, D.T., Fisher, D., Kosky, J.B., Homer, L.C., Reed, D.S., Cole, K.S., Trichel, A.M., Hartman, A.L. 2014. Development of novel mechanisms for housing, handling, and remote monitoring of common marmosets at animal biosafety level 3 (ABSL-3). Pathog Dis 71(2):219-226 PMID: 24453160
- Roy, C.J., Reed, D.S. 2012. Infectious disease aerobiology: miasma incarnate. Front Cell Inf Microbio. 2(163):1-2. PMID: 23267441
- Dupuy, L.C., Reed, D.S. 2012. Nonhuman Primate Models of Encephalitic Alphavirus Infection: Historical Review and Future Perspectives. Curr Opin Virol. 2(3):363-7 PMID: 22709522
- Bales, J.M., Powell, D.S., Bethel, L.M., Reed, D.S., Hartman, A.L. 2012. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever virus. Front Cell Inf Microbio 2(105):1-14. PMID: 22919694